ClinicalTrials.gg
RecruitingNCT07088068βETA PRESERVEUpdated Nov 13, 2026

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

A Phase 3 interventional study of Teplizumab and Placebo in Type 1 Diabetes Mellitus, sponsored by Sanofi. Recruiting at 201 sites in 20 countries. Open to participants aged 1 Year to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 13, 2026First site in SwitzerlandSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
723
Allocation
Randomized
Ages
1 Year to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Planned enrollment
Largest of 11
723 · median 60
Started
2025
with 1 other
Phase 3
3 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
3 of 11
Sanofi

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one has the largest planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 10th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 1 Year to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment.

The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) aged 1 to 25 years, on standard insulin therapy.

Read the detailed description

The study duration for one participant will be approximately 84 weeks (19 months).

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
1 Year to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Participant must be 1 to 25 years of age inclusive, at the time of signing the .
  • Participants diagnosed with T1D Stage 3 according to American Diabetes Association 2025 criteria
  • Participants able to be randomized and initiate study drug within 8 weeks (56 days) of the Stage 3 T1D diagnosis
  • Participants must be positive for at least one T1D autoantibody at screening:
  • Glutamic acid decarboxylase (GAD-65),
  • Insulinoma Antigen-2 (IA-2),
  • Zinc-transporter 8 (ZnT8), or
  • Insulin (if obtained not later than 14 days after exogenous insulin therapy initiation).
  • Islet cell cytoplasmic autoantibodies (ICAs)
  • Have random C-peptide level ≥0.2 nmol/L obtained at screening
  • Enter Inclusion Criteria Sex
  • Both male and female participants are eligible.
  • use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is eligible to participate if she is not pregnant, and one of the following conditions applies:
  • Is a woman of nonchildbearing potential (WONCBP) OR
  • Is a woman of (WOCBP) and agrees to use a contraceptive method that is highly effective, with a failure rate of \<1% during the study intervention period (to be effective before starting the intervention) and for at least 30 days after the last administration of study intervention.
  • A WOCBP must have a negative highly sensitive pregnancy test at screening (serum) and within 24 hours (urine or serum as required by local regulations) before the first administration of study intervention.
  • Lactating woman must interrupt breastfeeding and pump and discard breast milk during and for 20 days after last administration of study intervention.
  • Capable of giving signed informed consent as described in Appendix 1 of the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

Note: For minor participants, a specific ICF must also be signed by the participant's legally authorized representative (LAR).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participant has diabetes other than T1D that includes but is not limited to genetic forms of diabetes, maturity-onset diabetes of the young (MODY), diabetes secondary to medications or surgery and type 2 diabetes by judgement of the Investigator.
  • Participant has an active serious infection and/or fever ≥38.5°C (101.3°F) within the 48 hours prior to the first dose (except if localized skin infection), or has chronic, recurrent or opportunistic infectious disease.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with Epstein-Barr virus (EBV), cytomegalovirus (CMV).
  • At screening, participant has positive serology for (HIV), (HBV), or (HCV).
  • Participant has evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and/or TB testing. Blood testing (eg, QuantiFERON® TB Gold test) is strongly preferred; if not available, any local approved TB test is allowed.
  • Has other autoimmune diseases, (eg, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, systemic lupus erythematosus etc), except clinically stable autoimmune thyroid disease, or controlled celiac disease (at discretion of Investigator).
  • Any abnormality identified either in medical/surgical history or during screening evaluation (eg, physical examination, laboratory tests, vital signs), or any adverse event (AE) during screening period which, in the judgment of the investigator, would preclude safe completion of the study or constrains efficacy assessment.
  • Participant has recent or planned vaccinations as follows:
  • Live-attenuated (live) vaccines (eg, varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and smallpox) within the 8 weeks before first dose of the medicinal product (IMP) or planned/required administration during treatment or up to 26 weeks after last IMP administration in any treatment course
  • Inactivated or mRNA vaccines within 2 weeks before the first dose of IMP or planned required administration during treatment or up to 6 weeks after last IMP administration in any treatment course.
  • Current or prior use (within 30 days before screening) of any anti-hyperglycemic agents other than insulin
  • Past (within 30 days prior to screening) or current administration of any treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including but not limited to systemic (ie, oral, high doses of inhaled or injectable) with duration >14 days, adrenocorticotropic hormone, verapamil).
  • Past systemic medicine or immune modulatory biologic therapy (such as monoclonal antibodies), within 3 months or 5 half-lifes (whichever is longer) prior to dosing.
  • Current or prior (within 30 days before screening) use of any medication known to significantly influence glucose tolerance (eg, atypical antipsychotics, diphenylhydantoin, niacin).
  • Participant has previously received teplizumab or other anti-CD3 treatment.
  • Other medications not compatible or interfering with IMP at discretion of Investigator.
  • Current enrollment OR past participation in another investigational study in which an investigational intervention (eg, drug, vaccine, invasive device) was administered within the last 8 weeks or 5 half-lifes, whichever is longer, prior to screening.
  • Participant has any of the following laboratory parameters, at screening prior to first dose:
  • Lymphocyte count: \<1000/µL,
  • : \<1500/µL (\< 1000 /µL in participants with documented Duffy-null genotype),
  • count: \<150,000 platelets/µL,
  • : \<10 g/dL,
  • (AST) >2.0 × (ULN),
  • Alanine aminotransferase (ALT) >2.0 × ULN,
  • Total >1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
723 participants (estimated)

Study arms

  • Experimental
    Teplizumab

    Participants will receive teplizumab in increasing doses by intravenous administration

    Drug: Teplizumab

  • Placebo comparator
    Placebo

    Participants will receive volume matching placebo doses to the Teplizumab arm by intravenous administration

    Other: Placebo

Interventions

  • Pharmaceutical form: Concentrated solution for infusion Route of administration: Intravenous infusion

    Also known as: SAR446681, TZIELD

  • OtherPlacebo

    Pharmaceutical form: Concentrated solution for infusion Route of administration: Intravenous infusion

06

What researchers measure

Primary outcomes

  1. For United States (US) and non-European Union (EU) countries: Glycated hemoglobin (HbA1c) change from baseline

    Time frame: From Baseline to Week 52

  2. For US and non-EU countries: Total number of days without prandial insulin use

    Time frame: From baseline to Week 52

  3. For EU countries: Change from baseline in mean 2 hours mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from Area Under the Curve (AUC) in participants 5 years and older

    Time frame: From baseline to Week 52

  4. For EU countries: HbA1c change from baseline

    Time frame: From baseline to Week 52

  5. For EU countries: Total number of days without prandial insulin use

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Change from baseline in mean 2 hours MMTT stimulated C-peptide concentration, calculated from AUC

    Time frame: From baseline to Week 52

  2. Participants remaining C-peptide positive (2 hours MMTT stimulated peak C-peptide concentration ≥0.2 nmol/L)

    Time frame: At Week 52

  3. Incidence of participants with HbA1c ≤6.5% and requiring ≤0.25 IU/kg/day of insulin

    Time frame: At Week 52

  4. Change from baseline in Time-in-Range (TIR) (70-180 mg/dL blood glucose) assessed by continuous glucose monitoring (CGM)

    Time frame: From baseline to Week 52

  5. Number of level 2 and 3 (according to American Diabetes Association) hypoglycemic events per participant year (event rates)

    Time frame: From baseline to week 52

  6. Number of participants with treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and TEAEs leading to treatment discontinuation

    Time frame: From baseline to week 78

  7. Teplizumab PK parameters: Maximum concentration of teplizumab [Cmax]

    Time frame: From baseline to Week 30

  8. Teplizumab PK parameters: Area under the curve [AUC] and [AUClast]

    Time frame: From baseline to Week 30

  9. Incidence of antidrug-antibodies (ADAs)

    Time frame: From baseline to week 78

07

Study locations

200 of 201 sites recruiting
  • Scottsdale Clinical Trials- Site Number : 8400044
    Scottsdale, Arizona 85260, United States
    Recruiting
  • Rady Children's Hospital- Site Number : 8400002
    San Diego, California 92123, United States
    Recruiting
  • University of California San Francisco - Mission Bay- Site Number : 8400011
    San Francisco, California 94158, United States
    Recruiting
  • Barbara Davis Center for Childhood Diabetes- Site Number : 8400031
    Aurora, Colorado 80045, United States
    Recruiting
  • Yale University School of Medicine- Site Number : 8400005
    New Haven, Connecticut 06510, United States
    Recruiting
  • University of Florida College of Medicine- Site Number : 8400054
    Gainesville, Florida 32610, United States
    Recruiting
  • Encore Medical Research - Hollywood- Site Number : 8400061
    Hollywood, Florida 33024, United States
    Recruiting
  • Nemours Children's Speciality Care- Jacksonville- Site Number : 8400040
    Jacksonville, Florida 32207, United States
    Recruiting
  • University of South Florida- Site Number : 8400013
    Tampa, Florida 33612, United States
    Recruiting
  • AdventHealth Winter Park- Site Number : 8400033
    Winter Park, Florida 32792, United States
    Recruiting
  • Atlanta Diabetes Associates- Site Number : 8400036
    Atlanta, Georgia 30318, United States
    Recruiting
  • Children's Healthcare of Atlanta - Egleston Hospital- Site Number : 8400065
    Atlanta, Georgia 30322, United States
    Recruiting
  • IACT Health - Columbus - Talbotton Road- Site Number : 8400003
    Columbus, Georgia 31904, United States
    Recruiting
  • St. Luke's Children's Hospital- Site Number : 8400014
    Boise, Idaho 83712, United States
    Recruiting
  • Rocky Mountain Clinical Research - Idaho Falls- Site Number : 8400001
    Idaho Falls, Idaho 83404, United States
    Recruiting
  • Norton Children's Research Institute - Wendy Novak Diabetes Institute- Site Number : 8400016
    Louisville, Kentucky 40202, United States
    Recruiting
  • C.S. Mott Children's Hospital- Site Number : 8400015
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400019
    Rochester, Minnesota 55905, United States
    Recruiting
  • Park Nicollet Institute - Oncology Research- Site Number : 8400059
    Saint Louis Park, Minnesota 55426, United States
    Recruiting
  • Children's Mercy Adelle Hall Campus- Site Number : 8400010
    Kansas City, Missouri 64108, United States
    Recruiting
  • University At Buffalo - Jacobs School Of Medicine- Site Number : 8400006
    Buffalo, New York 14203, United States
    Recruiting
  • Endocrine Associates of West Village- Site Number : 8400064
    New York, New York 10001, United States
    Recruiting
  • Columbia University Irving Medical Center- Site Number : 8400009
    New York, New York 10032, United States
    Recruiting
  • Asheville Clinical Research- Site Number : 8400045
    Asheville, North Carolina 28803, United States
    Recruiting
  • UNC Children's Hospital- Site Number : 8400034
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • Cincinnati Children's Hospital Medical Center- Site Number : 8400018
    Cincinnati, Ohio 45229, United States
    Recruiting
  • The Ohio State University- Site Number : 8400051
    Columbus, Ohio 43210, United States
    Recruiting
  • The Children's Hospital of Philadelphia- Site Number : 8400039
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • AM Diabetes & Endocrinology Center- Site Number : 8400004
    Bartlett, Tennessee 38133, United States
    Recruiting
  • Baylor College of Medicine- Site Number : 8400057
    Houston, Texas 77030, United States
    Recruiting
  • University of Utah Health Hospital- Site Number : 8400052
    Salt Lake City, Utah 84132, United States
    Recruiting
  • Uva Children's Battle Building- Site Number : 8400060
    Charlottesville, Virginia 22903, United States
    Recruiting
  • Benaroya Research Institute at Virginia Mason- Site Number : 8400038
    Seattle, Washington 98101, United States
    Recruiting
  • MultiCare Mary Bridge Children's Health Center- Site Number : 8400037
    Tacoma, Washington 98405, United States
    Recruiting
  • Investigational Site Number : 0320008
    Mar del Plata, Buenos Aires 7600, Argentina
    Recruiting
  • Investigational Site Number : 0320003
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
    Recruiting
  • Investigational Site Number : 0320005
    Buenos Aires, 1419, Argentina
    Recruiting
  • Investigational Site Number : 0320013
    Córdoba, 5004, Argentina
    Recruiting
  • Investigational Site Number : 0320002
    Salta, 4400, Argentina
    Recruiting
  • Investigational Site Number : 0320012
    Santa Fe, 3000, Argentina
    Recruiting
  • Investigational Site Number : 0360001
    Brisbane, Queensland 4101, Australia
    Recruiting
  • Investigational Site Number : 0360003
    Adelaide, South Australia 5006, Australia
    Recruiting
  • Investigational Site Number : 0360002
    Perth, Western Australia 6009, Australia
    Recruiting
  • Investigational Site Number : 0560005
    Brussels, 1020, Belgium
    Recruiting
  • Investigational Site Number : 0560009
    Brussels, 1070, Belgium
    Recruiting
  • Investigational Site Number : 0560007
    Edegem, 2650, Belgium
    Recruiting
  • Investigational Site Number : 0560002
    Jette, 1090, Belgium
    Recruiting
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
    Recruiting
  • Investigational Site Number : 0560008
    Leuven, 3000, Belgium
    Recruiting
  • Investigational Site Number : 0560006
    Liège, 4000, Belgium
    Recruiting
  • Investigational Site Number : 0560004
    Namur, 5000, Belgium
    Recruiting
  • Hospital Universitario Walter Cantidio- Site Number : 0760009
    Fortaleza, Ceará 60430-270, Brazil
    Recruiting
  • Centro de Diabetes Curitiba- Site Number : 0760006
    Curitiba, Paraná 80810-040, Brazil
    Recruiting
  • Centro de Pesquisa Clínica de Marília - CPCLIM- Site Number : 0760002
    Marília, São Paulo 17504-072, Brazil
    Recruiting
  • Hospital Universitario Clementino Fraga Filho- Site Number : 0760008
    Rio de Janeiro, 21941-913, Brazil
    Recruiting
  • Centro de Pesquisas Clínicas - São Paulo- Site Number : 0760011
    São Paulo, 01228-200, Brazil
    Recruiting
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760012
    São Paulo, 05403-000, Brazil
    Recruiting
  • Hospital Israelita Albert Einstein- Site Number : 0760001
    São Paulo, 05651-901, Brazil
    Recruiting
  • Investigational Site Number : 1240008
    Calgary, Alberta T2N 4L7, Canada
    Recruiting
  • Investigational Site Number : 1240009
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
  • Investigational Site Number : 1240002
    Halifax, Nova Scotia B3H 2Y9, Canada
    Recruiting
  • Investigational Site Number : 1240007
    Ottawa, Ontario K1H 8L1, Canada
    Recruiting
  • Investigational Site Number : 1560035
    Beijing, 100020, China
    Recruiting
  • Investigational Site Number : 1560003
    Beijing, 100034, China
    Recruiting
  • Investigational Site Number : 1560033
    Beijing, 100045, China
    Recruiting
  • Investigational Site Number : 1560009
    Changchun, 130041, China
    Recruiting
  • Investigational Site Number : 1560001
    Changsha, 410011, China
    Recruiting
  • Investigational Site Number : 1560055
    Chengdu, 610072, China
    Recruiting
  • Investigational Site Number : 1560042
    Chengdu, 610091, China
    Recruiting
  • Investigational Site Number : 1560007
    Guangzhou, 510120, China
    Recruiting
  • Investigational Site Number : 1560037
    Guangzhou, 510620, China
    Recruiting
  • Investigational Site Number : 1560040
    Hangzhou, 310003, China
    Recruiting
  • Investigational Site Number : 1560014
    Hangzhou, 310009, China
    Recruiting
  • Investigational Site Number : 1560012
    Hangzhou, 310014, China
    Recruiting
  • Investigational Site Number : 1560010
    Harbin, 150001, China
    Completed

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 1560026
    Hohhot, 010050, China
    Recruiting
  • Investigational Site Number : 1560059
    Jinan, 250001, China
    Recruiting
  • Investigational Site Number : 1560056
    Lanzhou, 730000, China
    Recruiting
  • Investigational Site Number : 1560016
    Luoyang, 471003, China
    Recruiting
  • Investigational Site Number : 1560043
    Nanchang, 330038, China
    Recruiting
  • Investigational Site Number : 1560005
    Nanjing, 210008, China
    Recruiting
  • Investigational Site Number : 1560034
    Nanjing, 210008, China
    Recruiting
  • Investigational Site Number : 1560054
    Nanjing, 210029, China
    Recruiting
  • Investigational Site Number : 1560050
    Pingxiang, 337055, China
    Recruiting
  • Investigational Site Number : 1560031
    Shanghai, 200032, China
    Recruiting
  • Investigational Site Number : 1560032
    Shanghai, 200040, China
    Recruiting
  • Investigational Site Number : 1560013
    Shenyang, 110004, China
    Recruiting
  • Investigational Site Number : 1560045
    Shenzhen, 518026, China
    Recruiting
  • Investigational Site Number : 1560019
    Tianjin, 300052, China
    Recruiting
  • Investigational Site Number : 1560039
    Wuhan, 430010, China
    Recruiting
  • Investigational Site Number : 1560002
    Wuhan, 430030, China
    Recruiting
  • Investigational Site Number : 1560041
    Wuxi, 214023, China
    Recruiting
  • Investigational Site Number : 1560060
    Yueyang, 414000, China
    Recruiting
  • Investigational Site Number : 1560038
    Zhengzhou, 450018, China
    Recruiting
  • Investigational Site Number : 1560027
    Zhenjiang, 212000, China
    Recruiting
  • Investigational Site Number : 2030004
    Prague, 128 08, Czechia
    Recruiting
  • Investigational Site Number : 2030003
    Prague, 140 21, Czechia
    Recruiting
  • Investigational Site Number : 2030001
    Prague, 150 06, Czechia
    Recruiting
  • Investigational Site Number : 2500004
    Bron, 69500, France
    Recruiting
  • Investigational Site Number : 2500010
    La Tronche, 38700, France
    Recruiting

Showing the first 100 of 201 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2028, 34 months after the start.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 34 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2025
First posted
Jul 28, 2025
StartActual
Aug 6, 2025
Primary completionEst.
Jun 6, 2028
CompletionEst.
Dec 12, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 17 sites removed — first site in Switzerland. Investigational Site Number : 1560010 is now Completed
Show 21 added (12 Italy, 2 Switzerland, 2 Spain, 1 United States, 1 Canada, 1 Japan, 1 Germany, 1 Poland)
  • Rady Children's Hospital- Site Number : 8400002 · San Diego, United States
  • Investigational Site Number : 1240007 · Ottawa, Canada
  • Investigational Site Number : 3800016 · Pescara, Italy
  • Investigational Site Number : 3920008 · Shimajiri, Japan
  • Investigational Site Number : 7560002 · Basel, Switzerland
  • Investigational Site Number : 2760013 · Bad Mergentheim, Germany
  • Azienda Ospedaliera Universitaria Meyer IRCCS-Site Number: 3800001 · Florence, Italy
  • IRCCS Istituto Giannina Gaslini-Site Number: 3800008 · Genoa, Italy
  • AOU Policlinico Umberto I, UOC Diabetologia-Site Number: 3800012 · Rome, Italy
  • Ospedale Pediatrico Bambino Gesù-Site Number: 3800003 · Rome, Italy
  • Ospedale Infantile Regina Margherita - A.O.U. Città della Salute e della Scienza-Site Number: 3800010 · Turin, Italy
  • UOC Pediatria, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola-Site Number: 3800004 · Bologna, Italy
  • Policlinico Universitario di Messina -Site Number: 3800014 · Messina, Italy
  • AOU Maggiore della Carità-Site Number: 3800015 · Novara, Italy
  • "Ospedale "Santo Spirito" UOC di Pediatria Via Renato Paolini 47, Pescara"-Site Number: 3800016 · Pescara, Italy
  • Università degli Studi di Siena, Dip. Scienze Mediche Chirurgiche e Neuroscienze-Site Number: 3800013 · Siena, Italy
  • Azienda Ospedaliera Universitaria Integrata di Verona-Site Number: 3800002 · Verona, Italy
  • Investigational Site Number : 6160006 · Bialystok, Poland
  • Investigational Site Number : 7240003 · Sabadell, Spain
  • Investigational Site Number : 7240015 · Palma, Spain
  • Investigational Site Number : 7560001 · Bern, Switzerland
Show 17 removed
  • Investigational Site Number : 1560018 · Nanchang, China
  • Investigational Site Number : 2500007 · Strasbourg, France
  • Investigational Site Number : 3800001 · Florence, Italy
  • Investigational Site Number : 3800008 · Genoa, Italy
  • Investigational Site Number : 3800012 · Rome, Italy
  • Investigational Site Number : 3800003 · Rome, Italy
  • Investigational Site Number : 3800010 · Turin, Italy
  • Investigational Site Number : 3800004 · Bologna, Italy
  • Investigational Site Number : 3800014 · Messina, Italy
  • Investigational Site Number : 3800015 · Novara, Italy
  • Investigational Site Number : 3800016 · Pescara, Italy
  • Investigational Site Number : 3800013 · Siena, Italy
  • Investigational Site Number : 3800002 · Verona, Italy
  • Investigational Site Number : 6160006 · Bialystok, Poland
  • Investigational Site Number : 7240015 · Palma, Spain
  • Investigational Site Number : 7240003 · Sabadell, Spain
  • Investigational Site Number : 7560002 · Basel, Switzerland
across 2 updates, Oct 13, 2026 – Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Investigational Site Number : 3800005 · Milan, ItalyContact added g•••@unimi.it · •••5321Contact added c•••@unimi.it · •••5324Contact added (no phone or email listed)
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    16 sites added, 17 sites removed. Investigational Site Number : 1560010 is now Completed
    Show 16 added (11 Italy, 2 Spain, 1 Germany, 1 Poland, 1 Switzerland)
    • Investigational Site Number : 2760013 · Bad Mergentheim, Germany
    • Azienda Ospedaliera Universitaria Meyer IRCCS-Site Number: 3800001 · Florence, Italy
    • IRCCS Istituto Giannina Gaslini-Site Number: 3800008 · Genoa, Italy
    • AOU Policlinico Umberto I, UOC Diabetologia-Site Number: 3800012 · Rome, Italy
    • Ospedale Pediatrico Bambino Gesù-Site Number: 3800003 · Rome, Italy
    • Ospedale Infantile Regina Margherita - A.O.U. Città della Salute e della Scienza-Site Number: 3800010 · Turin, Italy
    • UOC Pediatria, IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola-Site Number: 3800004 · Bologna, Italy
    • Policlinico Universitario di Messina -Site Number: 3800014 · Messina, Italy
    • AOU Maggiore della Carità-Site Number: 3800015 · Novara, Italy
    • "Ospedale "Santo Spirito" UOC di Pediatria Via Renato Paolini 47, Pescara"-Site Number: 3800016 · Pescara, Italy
    • Università degli Studi di Siena, Dip. Scienze Mediche Chirurgiche e Neuroscienze-Site Number: 3800013 · Siena, Italy
    • Azienda Ospedaliera Universitaria Integrata di Verona-Site Number: 3800002 · Verona, Italy
    • Investigational Site Number : 6160006 · Bialystok, Poland
    • Investigational Site Number : 7240003 · Sabadell, Spain
    • Investigational Site Number : 7240015 · Palma, Spain
    • Investigational Site Number : 7560001 · Bern, Switzerland
    Show 17 removed
    • Investigational Site Number : 1560018 · Nanchang, China
    • Investigational Site Number : 2500007 · Strasbourg, France
    • Investigational Site Number : 3800001 · Florence, Italy
    • Investigational Site Number : 3800008 · Genoa, Italy
    • Investigational Site Number : 3800012 · Rome, Italy
    • Investigational Site Number : 3800003 · Rome, Italy
    • Investigational Site Number : 3800010 · Turin, Italy
    • Investigational Site Number : 3800004 · Bologna, Italy
    • Investigational Site Number : 3800014 · Messina, Italy
    • Investigational Site Number : 3800015 · Novara, Italy
    • Investigational Site Number : 3800016 · Pescara, Italy
    • Investigational Site Number : 3800013 · Siena, Italy
    • Investigational Site Number : 3800002 · Verona, Italy
    • Investigational Site Number : 6160006 · Bialystok, Poland
    • Investigational Site Number : 7240015 · Palma, Spain
    • Investigational Site Number : 7240003 · Sabadell, Spain
    • Investigational Site Number : 7560002 · Basel, Switzerland
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Investigational Site Number : 3800005 · Milan, ItalyContact added g•••@unimi.it · •••5321Contact added c•••@unimi.it · •••5324Contact added (no phone or email listed)
    + 2 other changes: verification date and references
  2. Oct 13, 2026
    5 sites added — first site in Switzerland
    Show 5 added (1 United States, 1 Canada, 1 Italy, 1 Japan, 1 Switzerland)
    • Rady Children's Hospital- Site Number : 8400002 · San Diego, United States
    • Investigational Site Number : 1240007 · Ottawa, Canada
    • Investigational Site Number : 3800016 · Pescara, Italy
    • Investigational Site Number : 3920008 · Shimajiri, Japan
    • Investigational Site Number : 7560002 · Basel, Switzerland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07088068
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 28, 2025
Start date
Aug 6, 2025
Primary completion
Jun 6, 2028 (estimated)
Completion
Dec 12, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion